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Abstract
Although pediatric research enjoyed significant benefits during the National Institutes of Health
(NIH) doubling era, the proportion of the NIH budget devoted to the pediatric-research portfolio
has declined overall. In light of this declining support for pediatric biomedical research, the
Federation of Pediatric Organizations held a topic symposium at the 2009 Pediatric Academic
Societies annual meeting as a forum for discussion of the past and future states of funding, the
rationale for directing public funds toward the understanding of child health and disease, and new
programs and paradigms for promoting child health research. This report of the symposium is
intended to disseminate more broadly the information presented and conclusions discussed to
encourage those in the child health research community to exert influence with policy makers to
increase the allocation of national funding for this underfunded area.
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The Physician Shortage Problem is Only 15 Years Away: The new federal health-care law will allow more people to access
affordable health care, but there may not be enough doctors to provide that care. According to an article in The Wall Street Journal
(Sataline S and Wong SS, April 12, 2010), we could be short as many as 150 000 physicians in the next 15 years (based on data
obtained from the Association of American Medical Colleges) even with an effort to increase the number of US doctors through new
medical schools and increased class sizes of existing schools. The highest demand will be for primary-care physicians. While there
may be more future physicians in the medical school pipelines, there has yet to be a proportionate increase in residency positions to
accommodate these higher numbers due to a cap on Medicare funding (which pays for residency training). This cap currently
prevents an increase in the available post-graduate training positions in proportion to the increasing numbers of students.
Unfortunately the new health-care law does not have a provision to increase funded residency slots but can shift funds from unfilled
slots into other residency programs that might increase their number of residency slots for primary care specialties (including
pediatrics).
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Although pediatric research enjoyed significant benefits during the National Institutes of
Health (NIH) doubling era, the proportion of the NIH budget devoted to the pediatric-
research portfolio has declined overall. The Federation of Pediatric Organizations held a
topic symposium at the 2009 Pediatric Academic Societies annual meeting as a forum for
discussion of the past and future states of funding, the rationale for directing public funds
toward the understanding of child health and disease, and new programs and paradigms for
promoting child health research. Although important new initiatives have been focused on a
range of both rare and common pediatric conditions, our main conclusion is that there is a
need to increase the future support for pediatric biomedical research and to expand the
number of opportunities for advancement in scientific investigations and care for children.
Pediatricians will need to offer new conceptual arguments and evidence about the longer-
term benefits for tomorrow’s adults of today’s investment in the health and well-being of
our pediatric populations.
CHILD HEALTH RESEARCH FUNDING: IS THAT SINKING FEELING OVER?
THE DECLINING INVESTMENT IN PEDIATRIC RESEARCH
Dr Gitterman focused on the declining investment in pediatric-research funding and its
failure to keep up with recent congressional attempts to promote research during the NIH
budget-doubling period as well as the most recent period in which the Bush administration
kept NIH funding relatively constant despite ongoing inflation.1 Such declines occurred
despite a continuing awareness in Congress that there was inadequate pediatric-research
support. Moreover, as pointed out by Dr Gitterman, Congress has acknowledged in the past
that research on children is highly beneficial to promoting not only their health but that of
the national population. For example, in 1995 Congress was “concerned that inadequate
attention and resources are devoted to pediatric research conducted and supported by NIH”
(H.R. report No. 209, 104th Congress, 1st session, 80–81, 1995) and that Congress does
indeed “recognize the substantial benefits that biomedical research offers to the health and
well-being of our Nation’s children…and intends to work with the NIH Director as it
explores ways to strengthen the NIH’s capacity to support and encourage extramural
pediatric research” (Senate report No. 145, 104th Congress, 1st session, 112, 1995).
In response, Congress established the Pediatric Research Initiative (PRI) (as part of the 2000
Children’s Health Act) to increase support for pediatric research, strengthen collaborative
efforts among NIH institutes and centers, speed the development of pediatric clinical drug
trials, and invest in training pediatric researchers. As part of the PRI, Congress authorized
$50 million for the NIH Office of the Director to support the PRI in fiscal-year 2001. The
Children’s Health Act became effective after the fiscal-year 2001 appropriations cycle, but
unfortunately, no future fiscal year’s appropriations included PRI funding. Dr Gitterman
highlighted the NIH’s overall budget and its pediatric-research funding across 3 time
periods: before doubling (fiscal-year 1992–1997); doubling (fiscal-year 1998–2003); and
after doubling (fiscal-year 2004–2009). The average annual NIH appropriations increased by
5.4%, 13.4%, and 1.3% in each period, respectively. The average annual pediatric-research
funding (actual grants, contracts, intramural research, and other mechanisms of support)
increased much less, by 4.7%, 11.5%, and 0.3% in each period, respectively. Between fiscal
years 2004 and 2007, the average NIH budget increase nearly flattened, to only 1.96%.
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During this period, average pediatric-research funding has dropped markedly lower, to
0.57%; estimated fiscal-year 2008 pediatric funding is at −0.5%. Although NIH
appropriations and pediatric-research funding increased in nominal amounts, the proportion
devoted to pediatrics has remained flat, as it has done since fiscal-year 1992 (Fig 1).2
PEDIATRIC RESEARCH: EMERGING OPPORTUNITIES FOR CHILD HEALTH
RESEARCH FUNDING THROUGH THE NIH AND THE EUNICE KENNEDY
SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND DEVELOPMENT
Dr Duane Alexander, director of the Eunice Kennedy Shriver National Institute of Child
Health and Development (NICHD), discussed the many opportunities for pediatric research
at the NICHD that are funded, first noting how the NIH and NICHD have organized their
research agenda. An overarching goal has been to build on established infrastructure,
sustaining and modernizing successful, long-standing programs, and developing coordinated
and shared pediatric resources. These approaches include creation of virtual networks,
speeding translation of new discoveries into clinical practice, growing multidisciplinary
teams and networks, pioneering studies as a foundation for future research, and capitalizing
on opportunities by using American Recovery and Reinvestment Act funds. The NICHD
supports more than 20 network and center programs targeted directly to pediatric research
(Table 1). The NICHD also supports more than 30 additional active programs of solicited
research targeted to pediatrics.
Regarding infrastructure, the NICHD supports a large variety of research training programs
for pediatricians, including Child Health Research Career Development Awards (>600
physician-scientists trained over the past 21 years, two-thirds of whom continued in research
careers and half of whom received subsequent NIH funding) and the Pediatric Scientist
Development Program (155 pediatricians trained over the past 20 years, three-fifths of
whom continued in research careers and half of whom received subsequent NIH funding).
Recently, the NICHD introduced the Pediatric Critical Care Career Development Program,
which has trained 15 critical care pediatricians in the past 5 years. More than 2500
pediatricians have taken advantage of the NIH loan-repayment program targeted specifically
to pediatrics, covering 26% of all NIH extramural loan-repayment applications. Pediatric
loan-repayment applicants have comparable success rates to other loan-repayment
applicants. Overall, loan-repayment recipients are more likely to remain in research careers
than similar unfunded applicants.
Regarding the inclusion of children in research, NIH policy requires investigators to include
children in clinical research unless they can justify not doing so. Across the NIH, 62.3% of
human-subjects grants included children (fiscal-year 2007). Preliminary analyses showed
that 87% of NICHD grants included children younger than 21 years, and 65% included
children younger than 18.
Regarding new programs at the NICHD, Dr Alexander commented specifically on the
Pediatric Pharmacology Research Units (PPRUs), which have successfully developed
infrastructure and conducted cooperative multisite clinical trials, as well as enhanced
training opportunities in pediatric pharmacology. The PPRUs focus on developmental
pharmacology to understand developmentally related changes in metabolism and response to
drugs, develop predictive models to evaluate response/toxicity for pediatric subpopulations,
develop and validate pharmacokinetic/pharmacodynamic assessments to help evaluate these
responses, and facilitate opportunities to participate in centers and a clinical trials network
dedicated to pediatric pharmacology. Related to the PPRU infrastructure, Congress passed
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the Best Pharmaceuticals for Children Act to conduct studies of off-patent or on-patent
drugs or biological agents for unmet children’s therapeutic health needs.
Among growing research opportunities through the NIH, Dr Alexander discussed the
Pediatric Medical Device Safety and Improvement Act, which stimulates research to
develop devices for pediatric use to help prevent, diagnose, mitigate, or cure disorders. The
NICHD cooperates through a trans-NIH group that works with the Agency for Healthcare
Research and Quality and the Food and Drug Administration to develop a research plan and
report to Congress. New opportunities include academic/industry collaborations and
partnerships to develop devices, response to NIH institute- and center-specific and trans-
NIH initiatives (eg, catheters for newborns), and translation of a range of devices for adult
diseases and conditions to pediatric diseases and conditions.
Dr Alexander also noted that the NICHD has supported pediatric components in the
National Center for Research Resources Clinical Translational Science Award (CTSA)
program, particularly the CTSA Consortium Child Health Oversight Committee. He noted
many opportunities for collaboration, including a distributed biobank for rare pediatric
diseases, support for pediatric medical devices, informatics, a national database for
translational research, outcome-measures development, and external partnership with the
Pediatric Academic Societies annual meeting.
Dr Alexander also discussed the growing number of multidisciplinary research programs.
The Newborn Screening Translation Research Network builds on Health Resources and
Services Administration and Centers for Disease Control data to develop and test new assays
for individual conditions by using common screening platforms; systematically introduce
tests nationwide; and develop new treatments for conditions once assays are available.
Dr Alexander then discussed the National Children’s Study (NCS), the largest long-term
study of children’s health and development ever conducted, which would follow
approximately 100 000 children and families from before birth to the age of 21. The NCS
was established under the rationale that children are especially vulnerable to adverse
environmental exposures, existing research is too limited in size and scope, and life-course
(longitudinal) designs are needed to correctly link multiple exposures and multiple
outcomes. Many collaborative research opportunities may be available through the NCS,
including add-on studies and planned analyses of core hypotheses and public-use data sets
by multiple investigators.
Last, Dr Alexander noted the many pediatric-research opportunities under the American
Recovery and Reinvestment Act, including Challenge Grants, Grand Opportunity Grants,
Administrative Supplements, Student/Teacher Supplements, Competitive Revisions, Autism
requests for applications, 2-year research project grants, expanded pay lines, extramural
research facilities, and other opportunities still being created in specific areas. High-priority
topics that are relevant to children have included alcohol and adolescents, asthma in
children, autism, childhood cancer, childhood obesity, childhood onset of mental disorders,
cleft lip and palate, hearing devices in children, immunization compliance, learning
disabilities, neonatal exposure to drugs of abuse, pediatric cardiology, pediatric medical
devices, pediatric rheumatic and musculoskeletal disease, science education, youth and HIV,
and many more.
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NEW PARADIGMS IN CHILD HEALTH RESEARCH FUNDING: THE
RATIONALE FOR THE PEDIATRIC RESEARCH CONSORTIA BILL
Although the NICHD remains extremely active and successful in providing research
opportunities for investigators, Dr Williams noted that the pediatric physician-scientist
workforce remains small and is not growing substantially. As reported recently by the
National Association of Children’s Hospitals and Related Institutions, the number of many
pediatric subspecialists, a surrogate for physician-scientists, is still critically low in many
academic health centers.3
Many obstacles confront investigators who seek to develop new treatments for pediatric
diseases.4 The time delay for application of new drugs to pediatric diseases is excessive, in
part because of a lack of translational research and early-phase, controlled therapeutic trials
in children. There is increased difficulty in carrying out translational research in children
because of smaller patient numbers, reluctance of parents to enroll children in
“experimental” trials,5 and the ethical dilemmas of enrolling children in phase I trials.6
There also is insufficient networking of pediatric programs for both basic research and
translational/clinical trials, particularly those that are focused on the pediatric antecedents to
adult diseases, which exert major costs on society.7
Cutting-edge research in the post-genomics era requires large-scale infrastructure for
applications in translational and clinical research. A prime example is the NIH National
Cancer Institute Comprehensive Cancer Program, which fosters innovative applications of
basic research to translational/clinical research and clinical trials by supporting
infrastructure required for innovative, collaborative, and multidisciplinary research focused
on cancer. To develop a similar approach for pediatric research, Dr Williams and others
established the National Pediatric Research Consortia to develop the Pediatric Research
Consortium Establishment Act via congressional mandate (ie, new money). As such, it
would become a mechanism to both enhance NIH funding of childhood diseases and
increase efficiency collaborative and translational research consistent with the NIH
roadmap. The development process has included general support of concept from all groups
involved, including the executive committee of the Association of Medical School Pediatric
Department Chairs, the American Pediatric Society and Society for Pediatric Research
councils, the National Association of Children’s Hospitals and Related Institutions, and the
American Academy of Pediatrics.
Specific legislation requesting authorization of the Pediatric Research Consortia Act was
introduced in the spring of 2009 as Senate Bill 353 and House of Representatives Bill 758
and is currently under legislative review. The purposes of the Pediatric Research Consortium
Establishment Act are to strengthen the pediatric-research portfolio of the NIH, establish
priorities for pediatric research; ensure adequacy of translational research, and facilitate
“spoke-and-wheel” conformation to include centers with smaller patient populations. The
act establishes the National Pediatric Research Program under the director of the NIH. It
could and should leverage support from multiple institutes for additional requests for
applications in disease-specific areas and strengthen justification and opportunity for new
money for pediatric research. Another major goal is to increase interinstitutional networking.
The consortium program is complementary to the NCS and major training programs in
pediatrics and also would complement the goals of CTSAs by emphasizing basic
translational research.
The act envisions 20 large centers or “national pediatric research and demonstration centers”
that support their own and collaborative smaller programs in a geographic region. These
centers will be better able to support basic, translational, and clinical research and training
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and demonstrate use of new diagnostics and therapies in the pediatric population. Funded
centers would provide excellent opportunities for transdisciplinary, mechanistic, and
translational approaches aimed at new discoveries, diagnoses, and therapies. The
longitudinal funding of expensive but necessary cores and shared services will support state-
of-the-art basic and translational research. This support will provide an enabling
“foundation” to enhance the quality and timeliness of research into pediatric diseases, speed
the development of new clinical trials, increase the competitiveness of pediatric researchers
across multiple funding mechanisms (including all institutes at the NIH), and ultimately
speed development of new therapies for childhood diseases.
INVESTMENT IN CHILD HEALTH RESEARCH: SMART MONEY, WELL
SPENT—HOW RESEARCH IN EARLY LIFE DISORDERS PAYS HUGE
DIVIDENDS IN ADULT HEALTH
Dr Dover discussed how investment in pediatric research in early life pays huge dividends
for the entire population over its life span. Over the past 20 to 30 years the United States has
led other Western countries in per-capita health care spending, in absolute value and as a
fraction of gross domestic product, yet our nation’s health, particularly our children’s health,
does not rank as highly. Reflecting on this issue and on Dr Gitterman’s data that showed a
decline in NIH spending on child health research, Dr Dover suggested that increased
spending on child health research would not only improve child health but also decrease the
expenditure for costly adult-onset diseases that have their origins in the pediatric age group.
He noted both past and present acceptance of the concept that healthy children equal healthy
adults and noted as examples the prevention of infectious diseases through vaccines, the
prevention of single-gene disorders that can lead to chronic adult diseases, successful
counseling against high-risk behavior, screening for environmental toxins, and protection of
the elderly from infections through “herd immunity.” Dr Dover summarized the paradigm of
investment in research for preemption and prevention of adult-onset diseases, outlined by Dr
Elias Zerhouni, former director of the NIH, in his presentation to Congress during the NIH
appropriations hearings before Congress in 2007 (fiscal-year 2008 budget request witness
appearance before the House and Senate Subcommittees on Labor, Health and Human
Services, Education Appropriations, Elias A. Zerhouni, MD, Director, NIH, March 6 and 19,
2007; ref 8) (Fig 2). Prevention in the pediatric age group of adult-onset disorders (eg,
cardiovascular diseases including coronary artery disease and hypertension, obesity, type 2
diabetes, adult cancers, certain psychiatric disorders, and even Alzheimer disease) through
increased research investments in pediatrics will reduce health care costs exponentially more
than trying to continue to treat these disorders after they clinically appear in adults.
This approach sets the stage for how pediatric research can lead to healthier adults through
research focused on genetic susceptibility to diseases. Future research aimed at finding
specific genes or networks of genes that directly link to and/or cause specific diseases would
allow an individualized approach to prevention and therapy. Research also should focus on
how the environment influences the expression of these genes, thereby allowing detection of
susceptibility to adult diseases long before they appear clinically. Dr Dover reviewed the
concept that the human genome has evolved in a manner that ensures sufficient variability in
the genetic code and flexibility in the controls of gene expression such that the human
species can readily adapt to changes in the environment. The varieties of adaptations that are
made over evolutionary time are focused on 2 absolute necessities. First, the species must
produce healthy individuals able to adapt as a developing fetus to the in utero environment
and as an infant to the immediate postnatal environment (successful reproduction). Second,
these children must grow old enough to also have children and to protect their young
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(propagation of the species). Thus, the susceptibility to adult-onset disorders is a byproduct
of evolution, which is essentially blind to the maladaptive consequences of older age.
Dr Dover reflected on the work of Barker, originator of the fetal-origins-of-adult-disease
hypothesis. Barker first noted that early death caused by cardiovascular disease was
inversely related to birth weight.9 Fetal growth is primarily the result of environmental
factors, including prepregnancy weight, maternal nutrition, and plasma nutrient substrate
composition and maternal exposure to toxins in the environment. Cigarette smoking, for
example, is a major cause of fetal growth restriction, through a variety of direct toxicity
mechanisms and impaired maternal health, as much as or more so than genetic growth
potential.10 More recent research by Barker and his now many followers has revealed
additional risks from fetal growth restriction of later-life insulin resistance, obesity,
pancreatic insulin-secretion failure, and type 2 diabetes.11–13 Such “adult-onset disorders”
are moving into the school-age population, where they are exacerbated by societal trends
toward high-calorie (particularly sugar) diets and sedentary lifestyle. Paradoxically, high
birth weights (>5 kg) increase risks of pediatric and adult-onset cancers.14
Dr Dover then demonstrated how pediatricians can manipulate gene expression early in
infancy to affect risks for later-life onset of adult diseases. He commented specifically on the
studies from Lucas’s group in the United Kingdom, which has strikingly shown that clinical
interventions by neonatologists and pediatricians to induce more rapid growth in preterm or
small-for-gestational-age infants lead to impaired insulin sensitivity in adolescents and
higher blood pressure.15,16 Adapting diet and exercise regimens to prevent or ameliorate
such rapid growth is an excellent target, therefore, for pediatricians to positively influence
the risk of later-life obesity, hypertension, and type 2 diabetes.
It has become apparent that environmental factors during prenatal and postnatal life can
have profound effects on the programming of intracellular signals, cell-cell interactions, and
metabolic pathways. These adaptations of the human genome can affect the onset of both
adult and childhood disorders. One might imagine that perinatologists and pediatricians may
be able to screen infants for increased risks to diseases by whole-genome analysis, searching
for variation in the genetic code and searching the epigenome for variations in gene
expression. The case for investment in pediatric research, therefore, is strong.
SUMMARY AND CONCLUSIONS
Pediatric-research funding has increased considerably less than the overall NIH budget,
decreasing from 13.1% in 1993 to 11.3% in 2005; this declining trend has continued and
worsened over the past 4 years. Furthermore, Congress has not yet appropriated new funds
for the bipartisan PRI that was central in the Children’s Health Act of 2000, and the NIH has
not, as a result, shifted its overall research support in favor of funding for pediatric research.
As a result, pediatric research is losing ground, and children, not just pediatric scientists,
will lose out on the critical need for new preventive measures and treatments of the many
diseases that they suffer. This decline in research funding is occurring despite a large
portfolio of research and training programs that are supported by the NICHD. New
initiatives for congressional support for child health research, such as the Pediatric Research
Consortium Act, are necessary to start providing the infrastructure to expand pediatric
research throughout the United States. Furthermore, research into the causes, preventions,
and treatments of diseases that begin very early in life will have a profound, lifelong impact
on disease burden and financial costs. Learning more through fundamental research about
the causes of intrauterine growth restriction, preterm birth, obesity, diabetes, inflammation,
allergy, genetic diseases, host-pathogen interactions, and how essential nutrients and
unnatural toxins affect brain development, among other examples, will lead to the promise
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of improved health, not just in childhood but also throughout the life of the individual and
on to future generations. Such efforts to improve child health should begin before delivery in
conjunction with our obstetric colleagues while recognizing that a healthy mother has a
much better chance of producing a healthy infant, child, and adolescent and a future healthy
adult. The principal point is that pediatric research has a much greater potential to preempt
and prevent the lifelong burden and financial cost of diseases than investigations directed at
problems that begin later in life.
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NIH budget and pediatric-research portfolio, fiscal-year 1992–2009 (in billions).1,2 Source:
NIH Office of the Budget. Note: The NIH defines pediatric research as “studies in all
categories of biomedical research (basic, clinical, epidemiologic, behavioral, prevention,
treatment, diagnosis, as well as outcomes and health services) that relate to diseases,
conditions, or the health/development of neonates, infants, children, and adolescents up to
the age of 21. (Reproduced with permission from Gitterman DP, Hay WW Jr. Pediatr Res.
2008;64[5]:464.)
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Investment in pediatric research to identify and treat adult-onset diseases in childhood leads
to significant cost savings and reduced burden of disease (fiscal-year 2008 budget request
witness appearance before the House and Senate Subcommittees on Labor, Health and
Human Services, Education Appropriations, Elias A. Zerhouni, MD, Director, NIH, March 6
and 19, 2007; Adapted from ref 8).
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TABLE 1
NICHD Network and Center Programs Targeted Directly to Pediatric Research
Autism Centers of Excellence
Community and Child Health





Pediatric Critical Care Network
Adolescent HIV Medicine Trials Network
DirectNet and TrialNet (diabetes)
Genomics, Proteomics, and Prematurity
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